Insight

New National Analysis Maps DKK 83.1 billion in Danish Research Funding for Life Science

Insight

New National Analysis Maps DKK 83.1 billion in Danish Research Funding for Life Science

A newly published analysis from Aarhus University gives international life science companies and R&D leaders the first consolidated overview of how Denmark's competitive research funding is structured, where it is concentrated, and how companies can tap into it. For organisations assessing Denmark as an R&D location or research partner, the 
analysis offers a clear, evidence-based starting point.

When

A new national baseline for Danish research funding

The Danish Centre for Studies in Research and Research Policy, Aarhus University (Dansk Center for Forskningsanalyse) has published a report commissioned by ten of the country's leading public and private research foundations. 

The analysis covers 18,214 competitive research grants awarded between 2018 and 2024, totalling DKK 83.1 billion. The foundations behind the initiative include the Danish National Research Foundation, Innovation Fund Denmark, Novo Nordisk Foundation, Lundbeck Foundation, LEO Foundation, Carlsbergfondet, Villum Fonden, VELUX FONDEN, Augustinus Fonden and Danmarks Frie Forskningsfond (Independent Research Fund Denmark), which initiated the project.

“Research funding plays a crucial role in the development of new knowledge and, consequently, in the development of our society. This is why Independent Research Fund Denmark initiated the analysis and a broad collaboration between the funding bodies. For the first time, the analysis provides us with an overall picture of how competitive research funding is distributed across the research landscape. This gives us a much stronger basis for making decisions about how best to support independent research in Denmark. This knowledge will also provide an important foundation as we develop Independent Research Fund Denmark’s forthcoming strategy.”

Søren Serritzlew
Chair of the Board of Danmarks Frie Forskningsfond (Independent Research Fund Denmark)

For international companies, the report is useful as a map: it shows which funding instruments exist, how they are distributed across fields, and how reliant different research areas are on specific foundations or grant types tidsskrift.dk.

Project grants dominate, but strategic investments carry concentrated weight

Project grants are the most common funding instrument, accounting for 49 % of all grants and 40 % of total funding. Combined with research leader grants, these project-oriented formats make up 56 % of grants and 55 % of total funding.

At the other end of the scale, strategic initiatives represent only 1 % of grants by number but 21 % of total funding, reflecting a small number of very large, typically non-competitive awards to centres and large-scale collaborations. 

For companies, this signals that Denmark's funding landscape combines a broad base of smaller, competitive project grants with a limited number of major strategic investments, two routes worth distinguishing when scoping a potential research collaboration. 

Life science funding channels for industry

Two findings from the underlying grant data are particularly relevant for life science companies:

  • 5 % of all grants by number were awarded under industry-linked researcher schemes (industrial postdoc and industrial PhD formats), creating a direct, funded channel for companies to engage doctoral-level and postdoctoral talent in collaborative research.
  • 12 % of total funding (DKK 9.8 billion) was allocated to innovation, commercialisation and development grants, the largest single component of which is Innovation Fund Denmark's Grand Solutions programme (DKK 5.3 billion across 357 grants).

These figures indicate that Danish research funding is not limited to academic-only projects. A meaningful share is structured specifically to support industry collaboration and the translation of research into application.

Natural sciences and health research attract the largest share of funding

The report's mapping of funding against the size of the Danish research population shows that natural sciences and medicine/health sciences attract disproportionately more competitive funding relative to the number of active researchers in those fields, compared with other main research areas.

What this means for R&D decisions

For R&D leaders and corporate headquarters evaluating Denmark, the analysis provides three concrete, decision-relevant signals:

  • Scale and continuity: DKK 83.1 billion awarded over seven years demonstrates sustained, large-scale public and private commitment to competitive research funding.
  • Sector concentration: natural sciences and health/medical research are prioritised areas, relevant to pharma, biotech, medtech and healthtech investment decisions.
  • Entry points for industry: dedicated grant types for industrial PhDs, postdocs, and innovation/commercialisation funding offer structured ways for companies to engage with Danish research without building a funding relationship from scratch.

Why choose Denmark for life science R&D

Get in touch

Explore research funding opportunities in Denmark

Looking to establish or expand your R&D activities in Denmark? Invest in Denmark can help you navigate the Danish research funding landscape, identify relevant research and industry partners, and understand the conditions for setting up a Danish presence.

Contact our life science team to discuss your plans:

Denmark

London

New-York

Silicon-Valley

Oslo

Paris

Toronto

Tokyo

Bangalore

Taipei

Shanghai